LT2785349T - Kombinuotas vėžio gydymas - Google Patents

Kombinuotas vėžio gydymas

Info

Publication number
LT2785349T
LT2785349T LT12795842T LT12795842T LT2785349T LT 2785349 T LT2785349 T LT 2785349T LT 12795842 T LT12795842 T LT 12795842T LT 12795842 T LT12795842 T LT 12795842T LT 2785349 T LT2785349 T LT 2785349T
Authority
LT
Lithuania
Prior art keywords
cancer
combination treatment
treatment
combination
Prior art date
Application number
LT12795842T
Other languages
English (en)
Lithuanian (lt)
Inventor
Barry Davies
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47295082&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2785349(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of LT2785349T publication Critical patent/LT2785349T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LT12795842T 2011-11-30 2012-11-30 Kombinuotas vėžio gydymas LT2785349T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161564975P 2011-11-30 2011-11-30
PCT/GB2012/052969 WO2013079964A1 (en) 2011-11-30 2012-11-30 Combination treatment of cancer

Publications (1)

Publication Number Publication Date
LT2785349T true LT2785349T (lt) 2019-12-10

Family

ID=47295082

Family Applications (1)

Application Number Title Priority Date Filing Date
LT12795842T LT2785349T (lt) 2011-11-30 2012-11-30 Kombinuotas vėžio gydymas

Country Status (26)

Country Link
US (2) US20140329786A1 (enExample)
EP (1) EP2785349B2 (enExample)
JP (1) JP6309454B2 (enExample)
KR (1) KR102035361B1 (enExample)
CN (1) CN103945849B (enExample)
AU (2) AU2012321110B2 (enExample)
CA (1) CA2856646C (enExample)
CY (1) CY1122624T1 (enExample)
DK (1) DK2785349T4 (enExample)
ES (1) ES2762250T5 (enExample)
FI (1) FI2785349T4 (enExample)
HR (1) HRP20191982T4 (enExample)
HU (1) HUE046667T2 (enExample)
IL (1) IL232530B (enExample)
LT (1) LT2785349T (enExample)
MX (1) MX367640B (enExample)
MY (1) MY175800A (enExample)
PH (1) PH12014500943A1 (enExample)
PL (1) PL2785349T5 (enExample)
PT (1) PT2785349T (enExample)
RS (1) RS59493B2 (enExample)
RU (1) RU2640485C2 (enExample)
SG (1) SG11201401471PA (enExample)
SI (1) SI2785349T2 (enExample)
SM (1) SMT201900708T1 (enExample)
WO (1) WO2013079964A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100048912A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
LT3628319T (lt) 2008-10-02 2024-03-25 Salix Pharmaceuticals, Inc. Hepatinės encefalopatijos gydymas rifaksiminu
EP2393827B1 (en) 2009-02-05 2015-10-07 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
SI3124481T1 (en) 2010-02-16 2018-06-29 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and their use
SG191724A1 (en) 2011-01-11 2013-08-30 Glaxosmithkline Llc Combination
WO2013096907A1 (en) * 2011-12-22 2013-06-27 Tokai Pharmaceuticals, Inc. Methods and compositions for combination therapy using p13k/mtor inhibitors
AU2013204533B2 (en) * 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
RS60976B1 (sr) * 2012-09-26 2020-11-30 Aragon Pharmaceuticals Inc Antiandrogeni za lečenje nemetastatskog kancera prostate koji je otporan na kastraciju
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
WO2014153215A1 (en) 2013-03-14 2014-09-25 University Of Maryland,Baltimore Office Of Technology Transfer Androgen receptor down-regulating agents and uses thereof
WO2015023710A1 (en) 2013-08-12 2015-02-19 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
JP6355724B2 (ja) * 2013-10-01 2018-07-11 ノバルティス アーゲー がんを治療するためのアフレセルチブと組み合わせたエンザルタミド
EP3718544A1 (en) * 2013-10-01 2020-10-07 Novartis AG Combination
US9566280B2 (en) 2014-01-28 2017-02-14 Massachusetts Institute Of Technology Combination therapies and methods of use thereof for treating cancer
EP3824908A1 (en) 2015-04-10 2021-05-26 Capsugel Belgium NV Abiraterone acetate lipid formulations
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
EP3487497B1 (en) 2016-07-21 2021-09-08 Hadasit Medical Research Services and Development Ltd. Combinations comprising ar antagonists or inhibitors for use in treating glioblastoma
ES2884064T3 (es) 2016-12-16 2021-12-10 Kangpu Biopharmaceuticals Ltd Composición combinada que comprende un compuesto benzoheterocíclico y un modulador de la vía de los receptores androgénicos y usos de la misma
CN107670048B (zh) * 2017-08-30 2019-04-26 南京明臻医药科技有限公司 具有协同抗癌活性的中间体药物和聚乙二醇偶联协同抗癌药物、及其制备方法和应用
US20190091339A1 (en) * 2017-09-22 2019-03-28 Dispersol Technologies, Llc Abiraterone-cyclic oligomer pharmaceutical formulations and methods of formation and administration thereof
AU2018351714A1 (en) 2017-10-16 2020-04-30 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
CN108486041A (zh) * 2018-03-28 2018-09-04 华南农业大学 PI3K/Akt信号通路在鸡胚成纤维细胞内对马立克氏病毒增殖的应用及其检测方法
EP3935068B1 (en) 2019-03-06 2023-09-06 Propella Therapeutics, Inc. Abiraterone prodrugs

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL297170A (enExample) 1963-04-04 1900-01-01
EP0100172B1 (en) 1982-07-23 1987-08-12 Imperial Chemical Industries Plc Amide derivatives
DK0633893T3 (da) 1992-03-31 2000-04-17 Btg Int Ltd 17-Substituerede steroider, der er nyttige ved cancerbehandling
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
GB9312853D0 (en) 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
EP0944388A4 (en) 1996-04-03 2001-08-16 Merck & Co Inc INHIBITORS OF FARNESYL PROTEIN TRANSFERASE
US6432947B1 (en) 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
KR100923172B1 (ko) 1997-06-27 2009-10-22 아브락시스 바이오사이언스, 엘엘씨 신규 약물 제제
CN1264381A (zh) 1997-08-05 2000-08-23 辉瑞产品公司 4－氨基吡咯并(3,2－d)嘧啶作为神经肽Y受体拮抗药
US6162804A (en) 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
JP2002517396A (ja) 1998-06-04 2002-06-18 アボット・ラボラトリーズ 細胞接着阻害抗炎症性化合物
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
EP1181296A1 (en) 1999-06-03 2002-02-27 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
DK1686130T3 (da) 2000-06-26 2009-04-06 Pfizer Prod Inc Pyrrolo-[2,3-d]-pyrimidinforbindelser som immunsuppressive midler
CA2420177C (en) 2000-08-31 2008-07-08 F. Hoffmann-La Roche Ag Quinazoline derivatives as alpha-1 adrenergic antagonists
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
AU2002248151B2 (en) 2000-12-01 2008-02-21 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1, A2A, and A3 receptor and uses thereof
US20020182204A1 (en) 2001-03-23 2002-12-05 Marie-Christine Bissery Combination of a taxane and a cyclin-dependent kinase
PT1474425E (pt) 2002-01-07 2006-09-29 Eisai Co Ltd Desazapurinas e sua utilizacao
TW200403058A (en) 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
BR0310026A (pt) 2002-05-17 2005-02-15 Aventis Pharma Sa Uso de docetaxel/doxorrubicina/ciclofosfamida em terapia adjuvante de câncer de mama e ovariano
ES2464157T3 (es) 2002-06-26 2014-05-30 Ono Pharmaceutical Co., Ltd. Remedios para enfermedades causadas por contracción o dilatación vascular
US20040138238A1 (en) 2002-08-08 2004-07-15 Dhanoa Dale S. Substituted aminopyrimidine compounds as neurokinin antagonists
US20030139427A1 (en) 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
WO2004021979A2 (en) 2002-09-06 2004-03-18 Smithkline Beecham Corporation PYRROLO[2, 3-d]PYRIMIDINE-4-YL AND PURIN-6-YL UREA COMPOUNDS
JP4796301B2 (ja) 2002-11-08 2011-10-19 プレジデント アンド フェロウズ オブ ハーバード カレッジ テクネチウム−９９ｍ及びレニウムで標識した小型作用剤及び組織、臓器及び腫瘍の画像化方法
US7524847B2 (en) 2002-12-04 2009-04-28 Eisai R&D Management Co., Ltd. Fused 1,3-dihydro-imidazole ring compounds
US7332525B2 (en) * 2003-01-17 2008-02-19 Castle Erik P Method of treatment of prostate cancer and composition for treatment thereof
EP1444982A1 (de) 2003-02-06 2004-08-11 Merckle Gmbh Verwendung von Purinderivaten als selektive Kinase-Inhibitoren
WO2004080463A1 (en) 2003-03-10 2004-09-23 Schering Corporation Heterocyclic kinase inhibitors: methods of use and synthesis
CN1720246A (zh) 2003-04-21 2006-01-11 捷克共和国乌斯塔夫化学与生物化学研究院 (嘌呤－6－基)氨基酸及其制备方法
FR2856685B1 (fr) 2003-06-25 2005-09-23 Merck Sante Sas Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
US8362017B2 (en) 2003-08-29 2013-01-29 Exelixis, Inc. C-kit modulators and methods of use
WO2005044181A2 (en) 2003-09-09 2005-05-19 Temple University-Of The Commonwealth System Of Higher Education Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
TW200526626A (en) 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
EP1684694A2 (en) 2003-11-21 2006-08-02 Array Biopharma, Inc. Akt protein kinase inhibitors
US7511159B2 (en) 2003-12-25 2009-03-31 Ono Pharmaceutical Co., Ltd. Azetidine ring compounds and drugs comprising the same
AU2005249380C1 (en) 2004-04-23 2012-09-20 Exelixis, Inc. Kinase modulators and methods of use
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
EP1848719B1 (en) 2004-12-28 2012-02-01 Exelixis, Inc. [1h-pyrazolo[3,4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases
FR2880540B1 (fr) 2005-01-13 2008-07-11 Aventis Pharma Sa Utilisation de derives de la purine comme inhibiteurs de la proteine hsp90
FR2880626B1 (fr) 2005-01-13 2008-04-18 Aventis Pharma Sa Derives de la purine, compositions les contenant et utilisation
WO2006091450A1 (en) 2005-02-18 2006-08-31 Lexicon Genetics Incorporated 4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds
JP2008531531A (ja) * 2005-02-23 2008-08-14 アストラゼネカ アクチボラグ 方法
KR101431407B1 (ko) 2005-05-13 2014-08-18 더 리전트 오브 더 유니버시티 오브 캘리포니아 디아릴히단토인 화합물
US20060281768A1 (en) 2005-06-10 2006-12-14 Gaul Michael D Thienopyrimidine and thienopyridine kinase modulators
US8163767B2 (en) 2005-07-14 2012-04-24 Astellas Pharma Inc. Heterocyclic Janus Kinase 3 inhibitors
WO2007025090A2 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
EP3311805B1 (en) 2005-08-31 2020-01-15 Abraxis BioScience, LLC Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
WO2007027941A2 (en) 2005-08-31 2007-03-08 Abraxis Bioscience, Llc. Compositions and methods for preparation of poorly water soluble drugs with increased stability
JP2009523812A (ja) 2006-01-19 2009-06-25 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド 融合へテロ二環式キナーゼ阻害剤
WO2007125310A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Pharmaceutical combinations of pk inhibitors and other active agents
EP2016077A2 (en) 2006-04-25 2009-01-21 Astex Therapeutics Limited Pharmaceutical compounds
EP3719018B1 (en) 2006-04-25 2025-08-27 Astex Therapeutics Ltd Purine and deazapurine derivatives as pharmaceutical compounds
JP2009534456A (ja) 2006-04-25 2009-09-24 アステックス、セラピューティックス、リミテッド 医薬化合物
WO2007125320A1 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Pharmaceutical compounds
AR064415A1 (es) 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de pirrolo-piperidinas y purinas,composiciones farmaceuticas que los contienen y usos en trastornos y/o enfermedades mediadas por pka y pkb.
CA2673472A1 (en) 2006-12-21 2008-07-03 Vertex Pharmaceuticals Incorporated 5-cyan0-4- (pyrrolo) [2, 3b] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors
AR064416A1 (es) 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
NZ585261A (en) * 2007-10-11 2011-10-28 Astrazeneca Ab Pyrrolo [2, 3 -d] pyrimidin derivatives as protein kinase b inhibitors
EP2393827B1 (en) * 2009-02-05 2015-10-07 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
MX2011008452A (es) * 2009-02-10 2011-12-16 Astrazeneca Ab Derivados de triazolo [4,3-b] piridazina y sus usos para el cancer de prostata.
WO2011029782A1 (en) * 2009-09-11 2011-03-17 Bayer Schering Pharma Aktiengesellschaft Substituted (heteroarylmethyl) thiohydantoins as anticancer drugs
BR112012027745A2 (pt) * 2010-04-27 2017-01-10 Univ Johns Hopkins método e composição imunogênica para tratamento de neoplásia

Also Published As

Publication number Publication date
MX2014006547A (es) 2014-07-09
WO2013079964A1 (en) 2013-06-06
RS59493B2 (sr) 2023-02-28
EP2785349A1 (en) 2014-10-08
CA2856646A1 (en) 2013-06-06
AU2012321110B2 (en) 2014-10-23
JP6309454B2 (ja) 2018-04-11
HUE046667T2 (hu) 2020-03-30
PT2785349T (pt) 2019-12-11
ES2762250T5 (es) 2023-01-05
AU2012321110A1 (en) 2013-06-20
RU2014119713A (ru) 2016-01-27
HRP20191982T4 (hr) 2023-01-06
IL232530A0 (en) 2014-06-30
EP2785349B2 (en) 2022-11-09
NZ625611A (en) 2016-10-28
SMT201900708T1 (it) 2020-01-14
RS59493B1 (sr) 2019-12-31
PL2785349T5 (pl) 2023-01-30
HRP20191982T1 (hr) 2020-02-07
SI2785349T1 (sl) 2019-12-31
BR112014012261A2 (pt) 2017-06-13
US20160151373A1 (en) 2016-06-02
FI2785349T4 (fi) 2023-02-09
EP2785349B1 (en) 2019-10-16
PL2785349T3 (pl) 2020-03-31
CN103945849A (zh) 2014-07-23
JP2015500225A (ja) 2015-01-05
ES2762250T3 (es) 2020-05-22
DK2785349T3 (da) 2020-01-02
DK2785349T4 (da) 2023-01-09
KR20140098799A (ko) 2014-08-08
US9737540B2 (en) 2017-08-22
AU2013205648B2 (en) 2015-02-05
KR102035361B1 (ko) 2019-11-08
CA2856646C (en) 2020-01-14
AU2013205648A1 (en) 2013-06-13
RU2640485C2 (ru) 2018-01-09
HK1202253A1 (en) 2015-09-25
SG11201401471PA (en) 2014-08-28
CY1122624T1 (el) 2021-03-12
IL232530B (en) 2018-07-31
CN103945849B (zh) 2017-04-26
MY175800A (en) 2020-07-09
PH12014500943A1 (en) 2014-06-30
US20140329786A1 (en) 2014-11-06
MX367640B (es) 2019-08-29
SI2785349T2 (sl) 2023-01-31

Similar Documents

Publication Publication Date Title
IL276362A (en) Cancer treatment methods
IL232530A0 (en) Combined cancer treatment
EP2760452A4 (en) METHODS OF TREATING CANCER
PH12014500248A1 (en) Treatment of breast cancer
SG10201508495VA (en) Combination treatment of cancer
IL232890A0 (en) Immunogenic therapy for cancer
ZA201307036B (en) Treatment of solid tumours
IL228430A0 (en) Cancer treatment
IL226247A0 (en) Cancer treatment methods
EP2903644A4 (en) TREATMENT OF CANCER
EP2640390A4 (en) METHODS OF TREATING CANCER
GB201217892D0 (en) Treatment of cancer
IL275636A (en) Medical combination for cancer treatment
GB201217890D0 (en) Treatment of cancer
IL237229A0 (en) Methods of treating cancer using lipoplatin
GB201121791D0 (en) Combination treatment of cancer
GB201121783D0 (en) Treatment of cancer
GB201222950D0 (en) Combination treatment of cancer
GB201222949D0 (en) Combination Treatment of Cancer
GB201208296D0 (en) Treatment of cancer
GB201017354D0 (en) Treatment of cancer
GB201017356D0 (en) Combination treatment of cancer
IL232266A0 (en) Cancer treatment methods
IL229109A0 (en) Cancer diagnosis